Ma Jiewen, Sun Wengang, Tang Liang, Yang Di
Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Front Med (Lausanne). 2022 Apr 19;9:873600. doi: 10.3389/fmed.2022.873600. eCollection 2022.
We report a case of Behçet's disease (BD) with a newly identified tissue factor pathway inhibitor (TFPI) gene mutation. The patient suffered from recurrent deep vein thrombosis and dural sinus thrombosis which could not be relieved by constant anticoagulation therapy. Slight relapsing oral lesion was the initial manifestation of BD but was neglected. Genital ulcers and ocular symptoms were manifest 8-month later than vascular involvement. The patient was diagnosed with BD at last and a novel mutation in TFPI was identified simultaneously. After administration with azathioprine and dexamethasone, the clinical symptoms were quickly gone and no relapse was found during 7-month follow-up.
我们报告了一例伴有新发现的组织因子途径抑制剂(TFPI)基因突变的白塞病(BD)病例。该患者患有复发性深静脉血栓形成和硬脑膜窦血栓形成,持续抗凝治疗无法缓解。轻微复发性口腔病变是BD的初始表现,但被忽视了。生殖器溃疡和眼部症状比血管受累晚8个月出现。该患者最终被诊断为BD,同时发现了TFPI的一个新突变。给予硫唑嘌呤和地塞米松后,临床症状迅速消失,在7个月的随访中未发现复发。